The stock of InspireMD Inc (NYSEMKT:NSPR) is a huge mover today! About 2.97M shares traded hands or 3703.60% up from the average. InspireMD Inc (NYSEMKT:NSPR) has declined 87.73% since March 9, 2016 and is downtrending. It has underperformed by 95.14% the S&P500.
The move comes after 9 months positive chart setup for the $5.51M company. It was reported on Oct, 12 by Barchart.com. We have $5.41 PT which if reached, will make NYSEMKT:NSPR worth $2.87M more.
Analysts await InspireMD Inc (NYSEMKT:NSPR) to report earnings on November, 8. They expect $-0.13 earnings per share, up 71.11% or $0.32 from last year’s $-0.45 per share. After $-0.19 actual earnings per share reported by InspireMD Inc for the previous quarter, Wall Street now forecasts -31.58% EPS growth.
InspireMD Inc (NYSEMKT:NSPR) Ratings Coverage
Out of 2 analysts covering InspireMD (NYSEMKT:NSPR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. InspireMD has been the topic of 2 analyst reports since January 7, 2016 according to StockzIntelligence Inc. The rating was initiated by Rodman & Renshaw on Thursday, January 7 with “Buy”. The firm earned “Buy” rating on Thursday, January 7 by H.C. Wainwright.
According to Zacks Investment Research, “InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company’s initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel.”
Another recent and important InspireMD Inc (NYSEMKT:NSPR) news was published by Benzinga.com which published an article titled: “8 Biggest Mid-Day Gainers For Tuesday” on October 11, 2016.
NSPR Company Profile
InspireMD, Inc., incorporated on February 29, 2008, is a medical device company. The Firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The Company’s MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet mesh and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company’s MGuard coronary product, MGuard Prime Embolic Protection System (MGuard Prime EPS), is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.